Keystone Investors PTE Ltd. Invests $3.53 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Keystone Investors PTE Ltd. purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, Holdings Channel.com reports. The firm purchased 8,880 shares of the biopharmaceutical company’s stock, valued at approximately $3,531,000.

A number of other hedge funds have also modified their holdings of ALNY. Groupama Asset Managment increased its stake in shares of Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the last quarter. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $895,816,000. Arrowstreet Capital Limited Partnership increased its stake in shares of Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after acquiring an additional 1,185,909 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $369,943,000. Finally, AQR Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 295.2% in the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after acquiring an additional 555,759 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 2.3%

Alnylam Pharmaceuticals stock opened at $282.85 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market capitalization of $37.76 billion, a price-to-earnings ratio of 77.28 and a beta of 0.29. Alnylam Pharmaceuticals, Inc. has a one year low of $281.77 and a one year high of $495.55. The company’s fifty day moving average price is $304.31 and its two-hundred day moving average price is $343.68.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s quarterly revenue was up 96.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.44) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 7,740 shares of company stock valued at $2,420,214 over the last 90 days. Corporate insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ALNY. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Wells Fargo & Company increased their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Finally, Jefferies Financial Group reissued a “hold” rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $463.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.